Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sutro Biopharma (STRO) EBIT (2017 - 2025)

Sutro Biopharma (STRO) has disclosed EBIT for 9 consecutive years, with $80.2 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 222.85% to $80.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$40.1 million through Dec 2025, up 83.16% year-over-year, with the annual reading at -$40.1 million for FY2025, 83.16% up from the prior year.
  • EBIT hit $80.2 million in Q4 2025 for Sutro Biopharma, up from -$48.5 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $80.2 million in Q4 2025 to a low of -$68.5 million in Q1 2025.
  • Historically, EBIT has averaged -$29.8 million across 5 years, with a median of -$40.7 million in 2022.
  • Biggest five-year swings in EBIT: plummeted 251.23% in 2024 and later soared 222.85% in 2025.
  • Year by year, EBIT stood at -$35.0 million in 2021, then plummeted by 40.49% to -$49.2 million in 2022, then soared by 187.67% to $43.2 million in 2023, then tumbled by 251.23% to -$65.3 million in 2024, then skyrocketed by 222.85% to $80.2 million in 2025.
  • Business Quant data shows EBIT for STRO at $80.2 million in Q4 2025, -$48.5 million in Q3 2025, and -$3.3 million in Q2 2025.